FI3569690T3 - Ihmisperäisiä bakteereja, jotka saavat aikaan regulatoristen T-solujen proliferaatiota tai kerääntymistä - Google Patents
Ihmisperäisiä bakteereja, jotka saavat aikaan regulatoristen T-solujen proliferaatiota tai kerääntymistä Download PDFInfo
- Publication number
- FI3569690T3 FI3569690T3 FIEP19178787.8T FI19178787T FI3569690T3 FI 3569690 T3 FI3569690 T3 FI 3569690T3 FI 19178787 T FI19178787 T FI 19178787T FI 3569690 T3 FI3569690 T3 FI 3569690T3
- Authority
- FI
- Finland
- Prior art keywords
- homologous
- bacterial strain
- sequence
- containing dna
- nucleotide sequence
- Prior art date
Links
- 210000003289 regulatory T cell Anatomy 0.000 title claims 7
- 238000009825 accumulation Methods 0.000 title claims 4
- 230000035755 proliferation Effects 0.000 title claims 4
- 241000894006 Bacteria Species 0.000 title 1
- 108020004414 DNA Proteins 0.000 claims 17
- 230000001580 bacterial effect Effects 0.000 claims 17
- 239000002773 nucleotide Substances 0.000 claims 17
- 125000003729 nucleotide group Chemical group 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000000796 flavoring agent Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims 2
- 229960000265 cromoglicic acid Drugs 0.000 claims 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 2
- 235000013355 food flavoring agent Nutrition 0.000 claims 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 2
- 229960004963 mesalazine Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 244000144725 Amygdalus communis Species 0.000 claims 1
- 235000011437 Amygdalus communis Nutrition 0.000 claims 1
- 229920000945 Amylopectin Polymers 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 235000016068 Berberis vulgaris Nutrition 0.000 claims 1
- 241000335053 Beta vulgaris Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 229920002488 Hemicellulose Polymers 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 1
- 229920000294 Resistant starch Polymers 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 235000020224 almond Nutrition 0.000 claims 1
- 230000002590 anti-leukotriene effect Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940124589 immunosuppressive drug Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims 1
- 229960000511 lactulose Drugs 0.000 claims 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- JABGXPCRNXUENL-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1N=CNC2=NC=N[C]12 JABGXPCRNXUENL-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 235000013379 molasses Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 1
- 235000021254 resistant starch Nutrition 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000012138 yeast extract Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/145—Clostridium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161565976P | 2011-12-01 | 2011-12-01 | |
| US201261607360P | 2012-03-06 | 2012-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3569690T3 true FI3569690T3 (fi) | 2024-11-18 |
Family
ID=48535050
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19178787.8T FI3569690T3 (fi) | 2011-12-01 | 2012-11-29 | Ihmisperäisiä bakteereja, jotka saavat aikaan regulatoristen T-solujen proliferaatiota tai kerääntymistä |
| FIEP21198256.6T FI3978598T3 (fi) | 2011-12-01 | 2012-11-29 | Ihmisperäisiä bakteereja, jotka indusoivat regulatoristen t-solujen proliferaatiota tai kertymistä |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21198256.6T FI3978598T3 (fi) | 2011-12-01 | 2012-11-29 | Ihmisperäisiä bakteereja, jotka indusoivat regulatoristen t-solujen proliferaatiota tai kertymistä |
Country Status (10)
| Country | Link |
|---|---|
| US (10) | US10238694B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP3569690B1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP6306507B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN104160014A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2892588A1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK3978598T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2994320T3 (cg-RX-API-DMAC7.html) |
| FI (2) | FI3569690T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1204008A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013080561A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| RU2013109251A (ru) | 2010-08-04 | 2014-09-10 | Томас Джулиус БОРОДИ | Композиции для трансплантации фекальной флоры и способы их получения и применения и устройства для их доставки |
| PL3072524T3 (pl) | 2010-10-07 | 2018-06-29 | California Institute Of Technology | Probiotyczne terapie dla autyzmu |
| EP3610881A1 (en) | 2011-03-09 | 2020-02-19 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CN104160014A (zh) * | 2011-12-01 | 2014-11-19 | 国立大学法人东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
| WO2013130773A2 (en) | 2012-02-29 | 2013-09-06 | Ethicon Endo-Surgery, Inc. | Compositions of microbiota and methods related thereto |
| BR112014024159A2 (pt) | 2012-03-29 | 2017-06-20 | Therabiome Llc | Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice. |
| WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| US10220089B2 (en) | 2012-08-29 | 2019-03-05 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| JP6506173B2 (ja) | 2012-11-23 | 2019-04-24 | セレス セラピューティクス インコーポレイテッド | 相乗的細菌組成物並びにその生成及び使用の方法 |
| EP2956006A4 (en) | 2013-02-04 | 2017-02-22 | Seres Therapeutics, Inc. | Methods of populating a gastrointestinal tract |
| EP3904502A3 (en) | 2013-02-04 | 2022-02-23 | Seres Therapeutics, Inc. | Compositions and methods |
| WO2014152338A1 (en) | 2013-03-14 | 2014-09-25 | Kabadi Mohan | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| US10076546B2 (en) | 2013-03-15 | 2018-09-18 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| AU2014352643A1 (en) * | 2013-11-25 | 2016-06-30 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| EP3082431A4 (en) * | 2013-12-16 | 2017-11-15 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| KR102377396B1 (ko) * | 2014-04-10 | 2022-03-22 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | Th17 세포의 유도를 위한 조성물 및 방법 |
| US20150322176A1 (en) * | 2014-04-16 | 2015-11-12 | University Of Guelph | Novel polysaccharide immunogens from clostridium bolteae isolated from autistic subjects and methods and uses thereof |
| FI3146065T3 (fi) * | 2014-05-19 | 2025-02-12 | Memorial Sloan Kettering Cancer Center | Menetelmiä ja koostumuksia clostridium difficile -infektion vähentämiseksi |
| US10124025B2 (en) | 2014-10-30 | 2018-11-13 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| AU2015339284B2 (en) | 2014-10-30 | 2021-08-05 | California Institute Of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| EP3212001A4 (en) | 2014-10-31 | 2018-04-25 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| PL3223835T3 (pl) | 2014-11-25 | 2025-03-31 | Memorial Sloan-Kettering Cancer Center | Mikrobiota jelitowa i gvhd |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| CN108138122B (zh) | 2014-12-23 | 2021-09-21 | 4D制药研究有限公司 | 免疫调控 |
| BR112017013274A2 (pt) | 2014-12-23 | 2018-02-06 | 4D Pharma Research Limited | polipeptídeo e imunomodulação |
| EP3242673A1 (en) * | 2015-01-07 | 2017-11-15 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Gastro-intestinal biomarkers for diagnosis and therapies of proteinopathies |
| WO2016183577A1 (en) | 2015-05-14 | 2016-11-17 | Crestovo Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| CN114470009A (zh) | 2015-05-22 | 2022-05-13 | 亚利桑那大学董事会 | 用于治疗自闭症谱系障碍及相关症状的方法 |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| HRP20191949T1 (hr) | 2015-06-15 | 2020-01-24 | 4D Pharma Research Limited | Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti |
| ME03511B (me) | 2015-06-15 | 2020-04-20 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| US20180193391A1 (en) * | 2015-06-22 | 2018-07-12 | President And Fellows Of Harvard College | Induction of lamina propria regulatory t cells |
| US9938558B2 (en) | 2015-06-25 | 2018-04-10 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| US10851399B2 (en) | 2015-06-25 | 2020-12-01 | Native Microbials, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| MX388995B (es) | 2015-06-25 | 2025-03-20 | Native Microbials Inc | Métodos, aparatos y sistemas para analizar cepas de microorganismos de comunidades heterogéneas complejas, predecir e indentificar sus relaciones funcionales e interacciones y seleccionar y sintetizar conjuntos microbianos basados en estos. |
| US20190087536A1 (en) * | 2015-09-09 | 2019-03-21 | uBiome. Inc | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with thyroid health issues |
| CN108430483B (zh) | 2015-11-03 | 2022-05-17 | 布里格姆及妇女医院股份有限公司 | 用于治疗和/或预防食物变态反应的治疗性微生物群 |
| SI3209310T1 (en) | 2015-11-20 | 2018-06-29 | 4D Pharma Research Limited | Compositions containing bacterial strains |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US20190247447A1 (en) * | 2015-11-24 | 2019-08-15 | Seres Therapeutics, Inc. | Designed bacterial compositions |
| EP3400285B1 (en) | 2016-01-07 | 2025-10-29 | Native Microbials, Inc. | Methods for improving milk production by administration of microbial consortia |
| JP6675752B2 (ja) * | 2016-02-23 | 2020-04-01 | 国立大学法人佐賀大学 | 腸内Ｂｌａｕｔｉａ ｃｏｃｃｏｉｄｅｓ増殖刺激剤 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| RS58869B1 (sr) | 2016-03-04 | 2019-08-30 | 4D Pharma Plc | Kompozicije koje sadrže blautia bakterijske sojeve za lečenje visceralne hipersenzitivnosti |
| WO2017160711A1 (en) | 2016-03-14 | 2017-09-21 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| WO2017160944A2 (en) | 2016-03-15 | 2017-09-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing graft versus host disease |
| CN109561725A (zh) * | 2016-06-10 | 2019-04-02 | N·V·努特里奇亚 | 患过敏症的风险和用于降低该风险的营养物 |
| KR102658297B1 (ko) * | 2016-06-14 | 2024-04-18 | 베단타 바이오사이언시즈, 인크. | 클로스트리디움 디피실레 감염의 치료 |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10722600B2 (en) | 2016-06-17 | 2020-07-28 | New York University | Methods and compositions for treating cancer |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| JP6408092B2 (ja) * | 2016-08-29 | 2018-10-17 | 国立大学法人 東京大学 | 糞便微生物叢を含む組成物 |
| BR112019006041A2 (pt) * | 2016-09-27 | 2019-09-03 | Board Of Regents, The University Of Texas System | métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| WO2018081550A1 (en) | 2016-10-28 | 2018-05-03 | Vedanta Biosciences, Inc. | Methods and compositions for preserving bacteria |
| US12285475B2 (en) * | 2016-11-01 | 2025-04-29 | Keio University | Bacterium capable of inducing TH1 cells |
| US11571446B2 (en) * | 2016-11-18 | 2023-02-07 | Sanford Bumham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CN110062806B (zh) * | 2016-12-13 | 2022-08-05 | 深圳华大生命科学研究院 | 粪厌氧棒杆菌(Anaerostipes caccae)及其应用 |
| CA3045098C (en) | 2016-12-23 | 2021-08-10 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
| WO2018126036A1 (en) | 2016-12-28 | 2018-07-05 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles including dosed microbial ensembles and inoculative microbial ensembles |
| AU2017386658A1 (en) | 2016-12-28 | 2019-07-25 | Native Microbials, Inc. | Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon |
| WO2018148220A1 (en) * | 2017-02-07 | 2018-08-16 | California Institute Of Technology | Modulation of gut microbiota in huntington's disease and rett syndrome |
| US10596206B1 (en) | 2017-03-14 | 2020-03-24 | Cornell University | Probiotic compositions and methods of use |
| CA3058943C (en) | 2017-04-03 | 2023-10-17 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
| US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
| WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| CN110913702A (zh) | 2017-04-28 | 2020-03-24 | 埃斯库斯生物科技股份公司 | 利用微生物的人造生物集合在反刍动物中用于支持谷物加强剂和/或能量加强剂饮食的方法 |
| EP3624818A4 (en) | 2017-05-19 | 2021-04-14 | Memorial Sloan-Kettering Cancer Center | METHODS AND COMPOSITIONS FOR REDUCING INFECTION OR COLONIZATION WITH LISTERIA MONOCYTOGENES |
| EP3630137B1 (en) | 2017-05-22 | 2023-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| JP2020521760A (ja) | 2017-05-26 | 2020-07-27 | クレストヴォ・ホールディングス・エルエルシー | 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法 |
| HUE059249T2 (hu) | 2017-06-14 | 2022-11-28 | 4D Pharma Res Limited | Baktériumtörzseket tartalmazó készítmények |
| SG11201912105PA (en) | 2017-06-14 | 2020-01-30 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| PL3638271T3 (pl) | 2017-06-14 | 2021-03-22 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| GB201709763D0 (en) * | 2017-06-19 | 2017-08-02 | Probi Ab | Biological materials and methods |
| CN111163785A (zh) * | 2017-08-04 | 2020-05-15 | 第二基因组股份有限公司 | 作为生物疗法的人罗斯拜瑞氏菌、挑剔真杆菌及其组合 |
| WO2019032572A1 (en) * | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES |
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
| US11701394B2 (en) | 2017-08-14 | 2023-07-18 | Seres Therapeutics, Inc. | Compositions and methods for treating cholestatic disease |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN111372596A (zh) | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
| CN111432826A (zh) | 2017-10-30 | 2020-07-17 | 赛里斯治疗公司 | 用于治疗抗生素耐药性的组合物和方法 |
| EP3476396A1 (en) * | 2017-10-31 | 2019-05-01 | Institut Gustave Roussy | Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same |
| EP3706767A4 (en) * | 2017-11-09 | 2021-12-15 | Vedanta Biosciences, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AN ALLERGY |
| US10507221B2 (en) | 2017-11-09 | 2019-12-17 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
| EP4410954A3 (en) * | 2017-12-11 | 2025-01-15 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
| US20200368293A1 (en) * | 2018-01-18 | 2020-11-26 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of cancer |
| EP3749751A4 (en) | 2018-02-09 | 2022-02-23 | Keio University | COMPOSITIONS AND METHODS FOR INDUCING CD8+ T LYMPHOCYTES |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CR20210001A (es) | 2018-07-10 | 2021-04-19 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2) |
| EP3594321A1 (en) * | 2018-07-10 | 2020-01-15 | Université catholique de Louvain | Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| CA3106315A1 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| DE102018213030A1 (de) * | 2018-08-03 | 2020-02-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien |
| IL280779B2 (en) | 2018-08-17 | 2025-05-01 | Vedanta Biosciences Inc | Compositions for use in the treatment or prevention of Clostridium difficile infection |
| WO2020069280A1 (en) | 2018-09-27 | 2020-04-02 | Crestovo Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
| JP7444459B2 (ja) * | 2018-10-04 | 2024-03-06 | 国立研究開発法人理化学研究所 | ＩＬＣ２を標的としたＩｇＡ産生誘導方法 |
| EP3876755A4 (en) * | 2018-11-05 | 2022-08-24 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIOUS, AUTOIMMUNE AND ALLERGIC DISEASES |
| WO2020234746A1 (en) | 2019-05-18 | 2020-11-26 | Janssen Biotech, Inc. | Materials and methods for microbiome modulation |
| KR20220063153A (ko) * | 2019-07-17 | 2022-05-17 | 유타대학연구재단 | 클로스트리디아 집합체 조성물 및 비만, 대사 증후군 및 과민성 대장 증후군을 치료하는 방법 |
| JP2022541795A (ja) | 2019-07-19 | 2022-09-27 | フィンチ セラピューティクス ホールディングス エルエルシー | 胃腸障害の治療のための方法および産物 |
| WO2021028585A1 (en) * | 2019-08-14 | 2021-02-18 | Wageningen Universiteit | Bacterium comprising myo-inositol to propionate pathway |
| WO2021033044A1 (en) | 2019-08-16 | 2021-02-25 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| US20250270498A1 (en) * | 2019-08-16 | 2025-08-28 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| EP4013851A1 (en) | 2019-08-16 | 2022-06-22 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| JP2021045097A (ja) * | 2019-09-20 | 2021-03-25 | 腸内フローラ移植臨床研究株式会社 | 腸内フローラの健康状態の診断方法及びその利用 |
| CN115243697A (zh) * | 2019-11-22 | 2022-10-25 | 未知君有限责任公司 | 包含细菌物种的组合物及其相关方法 |
| EP4125969A1 (en) * | 2020-03-25 | 2023-02-08 | Institut National de la Santé et de la Recherche Médicale (INSERM) | New strategy to treat and prevent diseases caused by enterobacteriae |
| EP3895710A1 (en) | 2020-04-15 | 2021-10-20 | DSM IP Assets B.V. | Food and/or feed compositions to manage immune homeostasis |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US20230201276A1 (en) * | 2020-05-21 | 2023-06-29 | Superbrewed Food, Inc. | Method of treating or preventing an infection |
| US12011467B2 (en) | 2021-05-18 | 2024-06-18 | J. Craig Venter Institute, Inc. | Bacterial formulation |
| CN116195742B (zh) * | 2021-11-30 | 2024-07-09 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99在保护软骨中的应用 |
| US20250025545A1 (en) * | 2021-12-02 | 2025-01-23 | Kanagawa Institute Of Industrial Science And Technology | Establishment of therapy and diagnosis for allergic diseases through control of immunoglobulin-binding protein |
| CN119970806A (zh) * | 2025-02-25 | 2025-05-13 | 浙江大学 | 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0029924B1 (en) | 1979-11-16 | 1984-08-15 | STEROSYNT Ltd. | 6-alpha-fluoro-16-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them |
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| US5700787A (en) | 1994-09-02 | 1997-12-23 | Brigham & Women's Hospital, Inc. | Capsular polysaccharide immunomodulator |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| WO1997034591A1 (en) | 1996-03-20 | 1997-09-25 | The University Of New South Wales | Alteration of microbial populations in the gastrointestinal tract |
| US6551632B2 (en) | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| JP2001112485A (ja) | 1999-10-19 | 2001-04-24 | Yakult Honsha Co Ltd | 腸内細菌用プライマー及び該プライマーを用いた検出方法 |
| FR2808689B1 (fr) | 2000-05-11 | 2004-09-03 | Agronomique Inst Nat Rech | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| SV2003000753A (es) | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico |
| WO2002080963A1 (en) | 2001-04-05 | 2002-10-17 | Virginia Mason Research Center | Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| PE20030283A1 (es) | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| GB0220809D0 (en) * | 2002-09-06 | 2002-10-16 | Univ College Of London | Immune modulator |
| GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| CA2520865A1 (en) | 2003-03-31 | 2004-10-21 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
| WO2004104175A2 (en) | 2003-05-14 | 2004-12-02 | University Of Georgia Research Foundation, Inc. | Probiotic bacteria and methods |
| JP2005124495A (ja) | 2003-10-24 | 2005-05-19 | Yakult Honsha Co Ltd | ヒト腸内細菌検出用プライマー |
| WO2005094886A1 (ja) | 2004-03-31 | 2005-10-13 | Kirin Beer Kabushiki Kaisha | Gpiアンカー蛋白質アゴニストによる調節性t細胞分化誘導・増殖方法およびそのための医薬組成物 |
| US8092793B2 (en) | 2004-12-15 | 2012-01-10 | Qingdao East Sea Pharmaceuticals, Ltd. | Treating inflammatory bowel disease with live bacteria |
| AU2006219475B8 (en) | 2005-03-03 | 2013-02-07 | Meiji Co., Ltd. | Immune function modulating agents |
| CU23581A1 (es) * | 2005-10-28 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer |
| WO2007092451A2 (en) | 2006-02-06 | 2007-08-16 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
| DE102006062250A1 (de) | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden |
| ES2399993T3 (es) | 2007-03-02 | 2013-04-04 | Protectimmun Gmbh | Composición farmacéutica para la protección frente a alergias y enfermedades inflamatorias |
| EP1974743A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics to Improve Gut Microbiota |
| CN101310730A (zh) | 2007-05-27 | 2008-11-26 | 青岛东海药业有限公司 | 酪酸梭菌在制备防治类风湿性关节炎、强直性脊柱炎微生物制剂中的应用 |
| JP2009084215A (ja) | 2007-09-28 | 2009-04-23 | Nippon Paper Chemicals Co Ltd | 炎症性腸疾患予防・治療剤 |
| WO2009050486A2 (en) | 2007-10-19 | 2009-04-23 | The University Of Surrey | Peptide manipulators of regulatory t cell activity |
| US20090124573A1 (en) | 2007-11-09 | 2009-05-14 | Sarkis Mazmanian | Immunomodulating compounds and related compositions and methods |
| CN101496819A (zh) | 2008-01-31 | 2009-08-05 | 青岛东海药业有限公司 | 真杆菌、梭菌制剂及其应用 |
| KR100913405B1 (ko) | 2008-03-25 | 2009-08-21 | 광주과학기술원 | Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물 |
| US8586029B2 (en) | 2008-06-04 | 2013-11-19 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
| JP2010129134A (ja) | 2008-11-28 | 2010-06-10 | Pulstec Industrial Co Ltd | ホログラム記録装置及びホログラム再生装置 |
| CN104655828B (zh) | 2009-02-13 | 2018-04-27 | 加州大学评议会 | 基于组织的诊断的系统、方法和装置 |
| GB0903016D0 (en) | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| US20100275282A1 (en) | 2009-04-23 | 2010-10-28 | Round June L | Methods and systems for identifying immunomodulatory substances |
| US20100311686A1 (en) | 2009-06-03 | 2010-12-09 | Kasper Lloyd H | Nutraceutical composition and methods for preventing or treating multiple sclerosis |
| WO2011005756A1 (en) | 2009-07-06 | 2011-01-13 | Puretech Ventures, Llc | Delivery of agents targeted to microbiota niches |
| WO2011022542A2 (en) | 2009-08-19 | 2011-02-24 | Puretech Ventures, Llc | Administration of factors normally present in a microbial niche to improve health |
| US20120149584A1 (en) | 2009-08-21 | 2012-06-14 | Bernat Olle | Methods of diagnosing and treating microbiome-associated disease using interaction network parameters |
| WO2011027956A2 (ko) | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델 |
| US20120276149A1 (en) * | 2009-10-15 | 2012-11-01 | Dan Littman | Methods for modulating bacterial infection |
| EP2498790A1 (en) | 2009-11-11 | 2012-09-19 | Alimentary Health Limited | A bifidobacterium strain |
| BR112012020003A2 (pt) * | 2010-02-10 | 2020-08-18 | Japan Eco-Science Co., Ltd. | mistura, solução de dissolução e agente farmacêutico cada um compreendendo micro-organismo termofílico |
| WO2011151941A1 (ja) * | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| US20120020941A1 (en) | 2010-07-26 | 2012-01-26 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
| EP2598155A2 (en) | 2010-07-26 | 2013-06-05 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
| ES2388662B1 (es) | 2010-11-10 | 2014-04-11 | Consejo Superior De Investigaciones Científicas (Csic) | Nuevas cepas de duganella aisladas de la rizosfera de olivo silvestre y cultivado y su uso en la producción de violaceína. |
| US20120279149A1 (en) * | 2011-05-04 | 2012-11-08 | Sebastian George Quinn | System and device for utilization of energy in buildings |
| US20140171339A1 (en) * | 2011-06-06 | 2014-06-19 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting adenomas, colorectal cancer, and uses thereof |
| WO2013037068A1 (en) | 2011-09-14 | 2013-03-21 | Queen's University At Kingston | Method for treatment of disorders of the gastrointestinal system |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CN104160014A (zh) | 2011-12-01 | 2014-11-19 | 国立大学法人东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| WO2014078911A1 (en) | 2012-11-26 | 2014-05-30 | Borody Thomas J | Compositions for the restoration of a fecal microbiota and methods for making and using them |
| EP2956006A4 (en) | 2013-02-04 | 2017-02-22 | Seres Therapeutics, Inc. | Methods of populating a gastrointestinal tract |
| WO2014152338A1 (en) | 2013-03-14 | 2014-09-25 | Kabadi Mohan | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| US20160040215A1 (en) | 2013-03-14 | 2016-02-11 | Seres Therapeutics, Inc. | Methods for Pathogen Detection and Enrichment from Materials and Compositions |
| US10076546B2 (en) | 2013-03-15 | 2018-09-18 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
| EP3019181A4 (en) * | 2013-07-09 | 2016-09-21 | Puretech Ventures Llc | COMPOSITIONS WITH COMBINATIONS OF BIOACTIVE MOLECULARS DERIVED FROM MICROBOTS FOR TREATING DISEASES |
| KR102377396B1 (ko) | 2014-04-10 | 2022-03-22 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | Th17 세포의 유도를 위한 조성물 및 방법 |
| WO2015198105A1 (en) | 2014-06-27 | 2015-12-30 | Telefonaktiebolaget L M Ericsson (Publ) | System and method for supporting time-sensitive services in a communication network |
| WO2016003536A1 (en) | 2014-06-30 | 2016-01-07 | Salix Pharmaceuticals, Inc. | Methods for retreating irritable bowel syndrome (ibs) |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| CA2987013C (en) | 2015-05-30 | 2022-05-31 | Japan Eco-Science Co., Ltd. | Probiotic or prebiotic, method for producing same, microbial preparation, health food, and medicine |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US9642281B1 (en) * | 2015-12-28 | 2017-05-02 | Martas Precision Slide Co., Ltd. | Buckle set for sliding rail of industrial rackmount chassis |
| WO2017160711A1 (en) * | 2016-03-14 | 2017-09-21 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| US20170290889A1 (en) | 2016-04-11 | 2017-10-12 | New York University | Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders |
| JP6792103B2 (ja) | 2016-06-01 | 2020-11-25 | 株式会社テックコーポレーション | 微細気泡水供給システム |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| US12285475B2 (en) | 2016-11-01 | 2025-04-29 | Keio University | Bacterium capable of inducing TH1 cells |
| CA3045098C (en) * | 2016-12-23 | 2021-08-10 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
| WO2019032572A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES |
| JP2019046634A (ja) * | 2017-08-31 | 2019-03-22 | パナソニックＩｐマネジメント株式会社 | 照明システム及びコントローラ |
| US10507221B2 (en) * | 2017-11-09 | 2019-12-17 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
-
2012
- 2012-11-29 CN CN201280068081.8A patent/CN104160014A/zh active Pending
- 2012-11-29 FI FIEP19178787.8T patent/FI3569690T3/fi active
- 2012-11-29 EP EP19178787.8A patent/EP3569690B1/en active Active
- 2012-11-29 JP JP2014526308A patent/JP6306507B2/ja active Active
- 2012-11-29 FI FIEP21198256.6T patent/FI3978598T3/fi active
- 2012-11-29 DK DK21198256.6T patent/DK3978598T3/da active
- 2012-11-29 EP EP24196410.5A patent/EP4477750A3/en active Pending
- 2012-11-29 EP EP12854485.5A patent/EP2785828B1/en active Active
- 2012-11-29 US US14/362,097 patent/US10238694B2/en active Active
- 2012-11-29 ES ES19178787T patent/ES2994320T3/es active Active
- 2012-11-29 CA CA2892588A patent/CA2892588A1/en active Pending
- 2012-11-29 EP EP21198256.6A patent/EP3978598B1/en active Active
- 2012-11-29 CN CN201810228890.XA patent/CN108676774B/zh active Active
- 2012-11-29 WO PCT/JP2012/007687 patent/WO2013080561A1/en not_active Ceased
- 2012-11-29 ES ES21198256T patent/ES2993669T3/es active Active
- 2012-11-29 DK DK19178787.8T patent/DK3569690T3/da active
- 2012-11-29 CN CN202310526067.8A patent/CN116942833A/zh active Pending
- 2012-11-29 HK HK15104633.8A patent/HK1204008A1/xx unknown
-
2016
- 2016-02-09 US US15/019,101 patent/US9649345B2/en active Active
- 2016-02-09 US US15/019,068 patent/US9642881B2/en active Active
-
2017
- 2017-03-28 US US15/471,493 patent/US10052353B2/en active Active
- 2017-04-14 US US15/487,553 patent/US10058578B2/en active Active
- 2017-11-06 JP JP2017213526A patent/JP6492151B2/ja active Active
-
2018
- 2018-04-27 US US15/964,285 patent/US10183045B2/en active Active
- 2018-10-15 US US16/160,004 patent/US10342832B2/en active Active
- 2018-10-25 US US16/170,344 patent/US10835559B2/en active Active
-
2019
- 2019-03-04 JP JP2019038453A patent/JP7097838B2/ja active Active
- 2019-05-31 US US16/427,899 patent/US10624933B2/en active Active
-
2020
- 2020-10-15 US US17/071,425 patent/US11547732B2/en active Active
-
2021
- 2021-01-18 JP JP2021005834A patent/JP7165218B2/ja active Active
-
2022
- 2022-10-21 JP JP2022168855A patent/JP7503273B2/ja active Active
-
2024
- 2024-05-30 JP JP2024087782A patent/JP2024129016A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3569690T3 (fi) | Ihmisperäisiä bakteereja, jotka saavat aikaan regulatoristen T-solujen proliferaatiota tai kerääntymistä | |
| JP2015500792A5 (cg-RX-API-DMAC7.html) | ||
| CA3101184A1 (en) | Designed bacterial compositions and uses thereof | |
| EP4632075A3 (en) | Method for reducing immunogenicity of rna | |
| Lee et al. | Porcine epidemic diarrhea virus infection: inhibition by polysaccharide from Ginkgo biloba exocarp and mode of its action | |
| JP2018039833A5 (cg-RX-API-DMAC7.html) | ||
| JP2017081972A5 (cg-RX-API-DMAC7.html) | ||
| JP2017527260A5 (cg-RX-API-DMAC7.html) | ||
| WO2009118411A3 (en) | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
| JP2015057436A5 (cg-RX-API-DMAC7.html) | ||
| EP3275450B1 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containing lactococcus chungangensis | |
| JP2013518914A5 (cg-RX-API-DMAC7.html) | ||
| WO2009093240A3 (en) | Erythropoietin and fibronectin compositions for bone regeneration | |
| CN106659753A (zh) | 包含龙眼肉提取物作为有效成分的骨疾病的预防、改善或治疗用组合物 | |
| US20210275606A1 (en) | Compositions comprising bacterial strains | |
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
| WO2018093237A3 (ko) | 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물 | |
| JP5865347B2 (ja) | ポリアミド化合物及びミトコンドリア遺伝子疾患治療用医薬組成物 | |
| UA96480C2 (ru) | Приготовление пригодной для хранения суспензии жизнеспособных яиц глистов | |
| Jetani et al. | Nucleic acid aptamers stabilize proteins against different types of stress conditions | |
| Theodorou et al. | Calcium channels blockers inhibit the signal transduction through the AtoSC system in Escherichia coli | |
| CN101590237A (zh) | 含有钙拮抗剂和叶酸的组合物的用途 | |
| JP2010195831A (ja) | ＩκＢキナーゼ阻害剤 | |
| WO2012156811A3 (en) | Compositions useful for the treatment of inflammatory disease or disorders | |
| JP5558353B2 (ja) | Ｌｃｋｓｈ２ドメイン結合の小分子阻害剤 |